ReviewNature reviews. Cardiology2021
Pharmacogenetics to guide cardiovascular drug therapy.
Review in Nature reviews. Cardiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 2 syntheses or guidelines pooled it, 121 citations in OpenAlex.
- Trends in Mendelian randomization in neurological disease research: a bibliometric analysis.Frontiers in neurology · 2025Pooled it
- Pharmacokinetic Markers of Clinical Outcomes in Severe Mental Illness: A Systematic Review.International journal of molecular sciences · 2023Pooled it
- Pharmacogenomics and chronotherapy of drug-induced cardioprotection in acute myocardial infarction.Nature communications · 2025Trial
- P2Y12-P-selectin-mediated platelet activation in a murine model of dengue-associated thrombocytopenia.EBioMedicine · 2026Article
- Association of ACE I/D polymorphism with blood pressure response to valsartan-hydrochlorothiazide combination therapy in hypertensive patients from Khyber Pakhtunkhwa, Pakistan.Pharmacogenomics · 2026Observational
- β-Adrenergic receptors as immunomodulators in T cells: mechanisms of neuroimmune crosstalk and pathophysiological implications.Molecular medicine (Cambridge, Mass.) · 2026Review
- Antithrombotic Therapy in Primary and Secondary Prevention of Coronary Artery Disease.Journal of clinical medicine · 2026Review
- Patient-centred anti-platelet therapy following coronary artery bypass graft surgery.Journal of thrombosis and thrombolysis · 2026Review
- CYP450 Metabolizer Phenotypes in a Turkish Emergency Cardiac Patient Cohort: A Descriptive Pharmacogenomic Study.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Sex Differences in Prognostic Implications of CYP2C19 Genotype After Drug-Eluting Stent Implantation.Journal of the American Heart Association · 2026Article
- Pharmacometabolomics Detects Unreported Clopidogrel Metabolites in the Urine of Kidney and Liver Transplant Recipients.Metabolites · 2026Article
- Precision medicine and personalized nursing in cardiovascular disease: clinical applications and frontier developments.Frontiers in cardiovascular medicine · 2026Review
- Challenges and prospects ofFrontiers in pharmacology · 2026Review
- Article
- From polygenic risk to digital twins: the future of personalised cardiovascular medicine.Frontiers in cardiovascular medicine · 2026Review
- Review
- Machine Learning for Warfarin Therapy: A Systematic Review.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Custom Gene Panel Analysis Identifies Novel Polymorphisms Associated with Clopidogrel Response in Patients Undergoing Percutaneous Coronary Intervention with Stent.International journal of molecular sciences · 2025Article
- A narrative review of research advancements in pharmacogenetics of cardiovascular disease and impact on clinical implications.NPJ genomic medicine · 2025Review
- Determination of the latent geometry of atorvastatin pharmacokinetics by transfer entropy to identify bottlenecks.BMC pharmacology & toxicology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Over the past decade, pharmacogenetic testing has emerged in clinical practice to guide selected cardiovascular therapies. The most common implementation in practice is CYP2C19 genotyping to predict clopidogrel response and assist in selecting antiplatelet therapy after percutaneous coronary intervention. Additional examples include genotyping to guide warfarin dosing and statin prescribing. Increasing evidence exists on outcomes with genotype-guided cardiovascular therapies from multiple randomized controlled trials and observational studies. Pharmacogenetic evidence is accumulating for additional cardiovascular medications. However, data for many of these medications are not yet sufficient to support the use of genotyping for drug prescribing. Ultimately, pharmacogenetics might provide a means to individualize drug regimens for complex diseases such as heart failure, in which the treatment armamentarium includes a growing list of medications shown to reduce morbidity and mortality. However, sophisticated analytical approaches are likely to be necessary to dissect the genetic underpinnings of responses to drug combinations. In this Review, we examine the evidence supporting pharmacogenetic testing in cardiovascular medicine, including that available from several clinical trials. In addition, we describe guidelines that support the use of cardiovascular pharmacogenetics, provide examples of clinical implementation of genotype-guided cardiovascular therapies and discuss opportunities for future growth of the field.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.